

Workshop in Multiple Sclerosis

Translating engineering innovation into the clinic

30th - 31st January 2018, University College London, London

THE CENTRAL VEIN SIGN

Dr Rosa Cortese

Clinical Research Associate

NMR Research Unit - Queen Square Multiple Sclerosis Centre

Department of Neuroinflammation, UCL Institute of Neurology



The Central Vein Sign Outline

- Background
- The Central Vein Sign in MS vs NMOSD
- Future work

The Central Vein Sign Outline

- Background
- The Central Vein Sign in MS vs NMOSD
- Future work

The Central Vein Sign in MS

1963

ON THE VESSEL-PLAQUE RELATIONS IN THE
BRAIN IN MULTIPLE SCLEROSIS

TORBEN FOG





Fig. 2.

Schematic drawing of periventricular plaque, composed of single perivascular cylinders.
Prolongation around a vessel perpendicular to the longitudinal axis is demonstrated.

The Central Vein Sign in MS



1963

ON THE VESSEL-PLAQUE RELATIONS IN THE
BRAIN IN MULTIPLE SCLEROSIS

TORBEN FOG






Fig. 2.

Schematic drawing of periventricular plaque, composed of single perivascular cylinders.
Prolongation around a vessel perpendicular to the longitudinal axis is demonstrated.



The Central Vein Sign in MS



7T T2*-weighted gradient-echo



The Central Vein Sign in MS



Grabner et al. J. Magn. Reson. Imaging 2011

Susceptibility Weighted Imaging (SWI) a **3T** enhances the contrast between tissue and allows the visualization of the anatomic relationship between the cerebral WMLs and the penetrating veins.

The Central Vein Sign in MS

2016

EXPERT CONSENSUS DOCUMENT

NATURE REVIEWS | NEUROLOGY

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

Pascal Sati¹, Jiwon Oh^{2,3}, R. Todd Constable⁴, Nikos Evangelou⁵, Charles R. G. Guttmann⁶, Roland G. Henry⁷, Eric C. Klawiter⁸, Caterina Mainero⁹, Luca Massacesi¹⁰, Henry McFarland¹, Flavia Nelson¹¹, Daniel Ontaneda¹², Alexander Rauscher¹³, William D. Rooney¹⁴, Amal P. R. Samaraweera⁵, Russell T. Shinohara¹⁵, Raymond A. Sobel¹⁶, Andrew J. Solomon¹⁷, Constantina A. Treaba⁹, Jens Wuerfel¹⁸, Robert Zivadinov¹⁹, Nancy L. Sicotte²⁰, Daniel Pelletier²¹ and Daniel S. Reich¹ on behalf of the NAIMS Cooperative

Box 2 | Radiological definition of a central vein

A central vein exhibits the following properties on T2*-weighted images:

- Appears as a thin hypointense line or small hypointense dot
- Can be visualized in at least two perpendicular MRI planes, and appears as a thin line in at least one plane
- Has a small apparent diameter (<2 mm)
- Runs partially or entirely through the lesion
- Is positioned centrally in the lesion (that is, located approximately equidistant from the lesion's edges and passing through the edge at no more than two places), regardless of the lesion's shape

Exclusion criteria for lesions:

- Lesion is <3 mm in diameter in any plane
- Lesion merges with another lesion (confluent lesions)
- Lesion has multiple distinct veins
- Lesion is poorly visible (owing to motion or other MRI-related artefacts)

The Central Vein Sign in MS

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Lancet Neurol 2017
Published Online

Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman, Kazuo Fujihara, Steven L Galetta, Hans Peter Hartung, Ludwig Kappos, Fred D Lublin, Ruth Ann Marrie, Aaron E Miller, David H Miller, Xavier Montalban, Ellen M Mowry, Per Soelberg Sorensen, Mar Tintoré, Anthony L Traboulsee, Maria Trojano, Bernard M J Uitdehaag, Sandra Vukusic, Emmanuelle Waubant, Brian G Weinshenker, Stephen C Reingold, Jeffrey A Cohen

High-priority areas for research:

*«The role in MS diagnosis of techniques to distinguish MS lesions from T2 hyperintensities in other condition (e.g. **central vein sign** on susceptibility weighted imaging)...is being explored»*

The Central Vein Sign Outline

- Background
- The Central Vein Sign in MS vs NMOSD
- Future work


The Central Vein Sign in MS vs NMOSD

Aim of the study

To assess the discriminatory value of the perivenous distribution of brain white matter lesions in NMOSD and MS on **susceptibility weighted imaging (SWI) at 3T**

The Central Vein Sign in MS vs NMOSD

Neuromyelitis optica spectrum disorder (NMOSD) is a severe, disabling disease of the CNS primarily affecting spinal cord and optic nerves



The Central Vein Sign in MS vs NMOSD

NMOSD is different from Multiple Sclerosis (MS)

Table	Comparison of characteristic MRI findings between NMOSD and MS	
	NMOSD	MS
Spinal cord	Longitudinally extensive lesion (≥ 3 vertebral segments)	Short, often multiple lesions
	Central/gray matter involvement	Peripheral/asymmetrical/often posterior
	T1 hypointensity common on acute lesions	T1 hypointensity rare
Optic nerve	Long-length/posterior-chiasmal lesions	Short-length lesions
Brain	Periependymal lesions surrounding the ventricular system (wide-based along the ependymal lining)	Dawson fingers (perpendicular to ventricles)/S-shaped U-fiber lesions, inferior lateral ventricle and temporal lobe lesions
	Hemispheric tumefactive lesions	Cortical lesions
	Lesions involving corticospinal tracts	Perivenous lesions
	"Cloud-like" enhancing lesions	Ovoid or ring/open-ring enhancing lesions
Others	Normal-appearing tissue involvement may be limited to lesional tracts and associated cortex	Normal-appearing white matter manifests tissue damage using special MRI techniques
	Lesional <i>myo</i> -inositol reduced on MRS	Lesional <i>N</i> -acetyl-aspartate reduced on MRS

Abbreviations: MRS = magnetic resonance spectroscopy; MS = multiple sclerosis; NMOSD = neuromyelitis optica spectrum disorder.

MS-like lesions may appear in **10% to 12.5%** of NMOSD patients

The Central Vein Sign in MS vs NMOSD

Treatments used in MS may exacerbate NMOSD

OBSERVATION

Interferon Beta Treatment in Neuromyelitis Optica

Increase in Relapses and Aquaporin 4 Antibody Titers

Jacqueline Palace, DM; Maria Isabel Leite, DPhil; Angela Nairne, MRCP; Angela Vincent, *FRCPath*
Arch Neurol. 2010;67(8):1016-1017

Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

Ingo Kleiter, MD; Kerstin Hellwig, MD; Achim Berthele, MD; Tania Kümpfel, MD; Ralf A. Linker, MD;
Hans-Peter Hartung, MD; Friedemann Paul, MD; Orhan Aktas, MD;
for the Neuromyelitis Optica Study Group

Arch Neurol. 2012;69(2):239-245

Case Study

**Development of extensive brain lesions
following fingolimod (FTY720) treatment
in a patient with neuromyelitis optica
spectrum disorder**

Ju-Hong Min, Byoung Joon Kim and Kwang Ho Lee

MULTIPLE
SCLEROSIS
JOURNAL

MSJ

Multiple Sclerosis Journal
18(1) 113-115
© The Author(s) 2012
Reprints and permission:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1352458511431973
msj.sagepub.com



The Central Vein Sign in MS vs NMOSD

Cohort description


	NMOSD(*)	RRMS(**)	HC
No. of patients	18	18	25
Gender (male/ female)	4/14	4/14	7/18
Age, y, mean [± SD]	52.5 [±2.8]	41.8 [±2.8]	37.1 [±2.4]
Disease duration, years, mean [± SD]	8.6 [± 7.3]	9 [± 6.4]	NA
EDSS, median (range)	5 (2 – 6.5)	2.5 (1 – 7.5)	NA

* 2006 Revised criteria for NMO


**2010 Diagnostic criteria for MS

The Central Vein Sign in MS vs NMOSD



Methods: image analysis



T2



PD



SWI


Brain MRI: Philips Achieva 3T

3D-FFE sequence with shifted echo
(voxel size $1 \times 1 \times 1 \text{ mm}^3$, reconstructed to $0.5 \times 0.5 \times 0.5 \text{ mm}^3$).


The Central Vein Sign in MS vs NMOSD

Methods: image analysis


Manual lesion detection



Infratentorial
Periventricular
Subcortical



SWI + Lesion Mask




Two readers blinded to
clinical data

The Central Vein Sign in MS vs NMOSD

Methods: image analysis



Dark line coursing through the lesion




Dark dot tracked on contiguous slices


The Central Vein Sign in MS vs NMOSD

Results

MS
80% CVS




NMOSD
32% CVS



OR=1.10
95%CI 1.04 to 1.16, p=0.001

The Central Vein Sign in MS vs NMOSD

Results



Accuracy: 94%
 (95%CI 81.34, 99.32, $p < 0.001$,
 sensitivity/specificity: 90%/100%).

The Central Vein Sign in MS vs NMOSD

Conclusion

The CVS on SWI at 3T MRI may differentiate MS from NMOSD.

Limitation

Procedure time-consuming



The Central Vein Sign Outline


- Background
- The Central Vein Sign in MS vs NMOSD
- Future work

Future work

Less time-consuming algorithms

«PICK 6»

1. If there are **six or more** morphologically characteristic lesions
2. if there are fewer than six morphologically characteristic lesions, but morphologically characteristic lesions **outnumber** non-perivenous lesions
3. if **neither** of these conditions are met




**INFLAMMATORY
DEMYELINATION**

**NO INFLAMMATORY
DEMYELINATION**

Future work

Automatic vessel segmentation




Future work

Automatic vessel segmentation

Vein anatomy



Image contrast



The accuracy of automated vein segmentations derived from the **composite vein image** was overwhelmingly superior to segmentations derived from SWI or QSM alone.

THANK YOU

